Literature DB >> 17918967

Detection and structural characterization of glutathione-trapped reactive metabolites using liquid chromatography-high-resolution mass spectrometry and mass defect filtering.

Mingshe Zhu1, Li Ma, Haiying Zhang, W Griffith Humphreys.   

Abstract

The present study was designed to apply the mass defect filter (MDF) approach to the screening and identification of reactive metabolites using high-resolution mass spectrometry. Glutathione (GSH)-trapped reactive metabolites of acetaminophen, diclofenac, carbamazepine, clozapine, p-cresol, 4-ethylphenol, and 3-methylindole in human liver microsomes (HLM) were analyzed by HPLC coupled with Orbitrap or Fourier transform ion cyclotron resonance mass spectrometry. Through the selective removal of all ions that fall outside of the GSH adduct MDF template windows, the processed full scan MS chromatograms displayed GSH adducts as major components with no or a few interference peaks. The accurate mass LC-MS data sets were also utilized for the elimination of false positive peaks, detection of stable oxidative metabolites with other MDF templates, and determination of metabolite molecular formulas. Compared to the neutral loss scan by a triple quadrupole instrument, the MDF approach was more sensitive and selective in screening for GSH-trapped reactive metabolites in HLM and rat bile and far more effective in detecting GSH adducts that do not afford the neutral loss of 129 Da as a significant fragmentation pathway. The GSH adduct screening capability of the MDF approach, together with the utility of accurate mass MS/MS information in structural elucidation, makes high-resolution LC-MS a useful tool for analyzing reactive metabolites.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17918967     DOI: 10.1021/ac071119u

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  19 in total

1.  MS(M), an efficient workflow for metabolite identification using hybrid linear ion trap Orbitrap mass spectrometer.

Authors:  Robert Cho; Yingying Huang; Jae C Schwartz; Yan Chen; Timothy J Carlson; Ji Ma
Journal:  J Am Soc Mass Spectrom       Date:  2012-02-14       Impact factor: 3.109

2.  Post-acquisition data processing for the screening of transformation products of different organic contaminants. Two-year monitoring of river water using LC-ESI-QTOF-MS and GCxGC-EI-TOF-MS.

Authors:  S Herrera López; M M Ulaszewska; M D Hernando; M J Martínez Bueno; M J Gómez; A R Fernández-Alba
Journal:  Environ Sci Pollut Res Int       Date:  2014-06-22       Impact factor: 4.223

Review 3.  Drug metabolite profiling and identification by high-resolution mass spectrometry.

Authors:  Mingshe Zhu; Haiying Zhang; W Griffith Humphreys
Journal:  J Biol Chem       Date:  2011-06-01       Impact factor: 5.157

Review 4.  Fourier transform mass spectrometry.

Authors:  Michaela Scigelova; Martin Hornshaw; Anastassios Giannakopulos; Alexander Makarov
Journal:  Mol Cell Proteomics       Date:  2011-07       Impact factor: 5.911

5.  The Opportunities of Metabolomics in Drug Safety Evaluation.

Authors:  Pengcheng Wang; Amina I Shehu; Xiaochao Ma
Journal:  Curr Pharmacol Rep       Date:  2017-01-03

6.  Deep Learning to Predict the Formation of Quinone Species in Drug Metabolism.

Authors:  Tyler B Hughes; S Joshua Swamidass
Journal:  Chem Res Toxicol       Date:  2017-02-02       Impact factor: 3.739

7.  Simultaneous screening of glutathione and cyanide adducts using precursor ion and neutral loss scans-dependent product ion spectral acquisition and data mining tools.

Authors:  Wenying Jian; Hua-Fen Liu; Weiping Zhao; Elliott Jones; Mingshe Zhu
Journal:  J Am Soc Mass Spectrom       Date:  2012-03-06       Impact factor: 3.109

8.  Profiling the reactive metabolites of xenobiotics using metabolomic technologies.

Authors:  Feng Li; Jie Lu; Xiaochao Ma
Journal:  Chem Res Toxicol       Date:  2011-04-21       Impact factor: 3.739

9.  The Application of Mass Spectrometry in Drug Metabolism and Pharmacokinetics.

Authors:  Ji-Yoon Lee; Sang Kyum Kim; Kiho Lee; Soo Jin Oh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

10.  The pneumotoxin 3-methylindole is a substrate and a mechanism-based inactivator of CYP2A13, a human cytochrome P450 enzyme preferentially expressed in the respiratory tract.

Authors:  Jaime D'Agostino; Xiaoliang Zhuo; Mohammad Shadid; Daniel G Morgan; Xiuling Zhang; W Griffith Humphreys; Yue-Zhong Shu; Garold S Yost; Xinxin Ding
Journal:  Drug Metab Dispos       Date:  2009-07-16       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.